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Abstract
Thirty years after its beginning, the HIV/AIDS epidemic is still raging around the world. According to UNAIDS,
in 2011 alone 1.7M deaths were attributable to AIDS, and 2.5M people were newly infected by the virus. Despite
the success in treating HIV-infected people with potent antiretroviral drugs, preventing HIV infection is the key
to ending the epidemic. Recently, the efficacy of topical and systemic antiviral chemoprophylaxis (i.e., pre-
exposure prophylaxis or ‘‘PrEP’’), using the same drugs used for HIV treatment, has been demonstrated in a
number of clinical trials. However, results from other trials have been inconsistent, especially those evaluating
PrEP in women. These inconsistencies may result from our incomplete understanding of pharmacokinetics
(PK)/pharmacodynamics (PD) at the mucosal sites of sexual transmission: the male and female gastrointestinal
and reproductive tracts. The drug concentrations used in these trials were derived from those used for treatment;
however, we still do not know the relationship between the therapeutic and the preventive dose. This article
presents the first comprehensive review of the available data in the HIV pharmacology field from animal models
to human studies, and outlines gaps, challenges, and future directions. Addressing these pharmacological gaps
and challenges will be critical in selecting and advancing future PrEP candidates and strategies with the greatest
impact on the HIV epidemic.
Introduction
Over the past 2 years, results from multiple clinicaltrials have been published evaluating the efficacy of
different antiretroviral (ARV)-based strategies for the pre-
vention of human immunodeficiency virus (HIV) transmis-
sion (Table 1). Unfortunately, results from these studies have
been inconsistent. For example, 1% tenofovir (TFV) vaginal
gel demonstrated a 39% reduction in HIV transmission to
women in the Phase 2b Centre for the AIDS Programme of
Research in South Africa (CAPRISA) 004 study conducted
using the coitally related ‘‘BAT-24’’ dosing regimen.1 In con-
trast, evaluation of once-daily use of 1% TFV gel was dis-
continued in the Microbicide Trials Network 003 Vaginal and
Oral Interventions to Control the Epidemic (VOICE) trial due
to a lack of effect relative to placebo.2
Results from trials evaluating oral ARV strategies have
been similarly divergent. Daily oral use of Truvada [200 mg
emtricitabine (FTC)–300 mg tenofovir disoproxil fumarate
(TDF)] was shown to be efficacious in a population of men
who have sex with men (MSM) in the Preexposure Prophy-
laxis (PrEP) Initiative (iPrEX) study,3 as well as in ser-
odiscordant couples in the Partners PrEP and TDF2 studies.4–7
Although efficacy results for these studies were statistically
significant, the confidence intervals were quite wide, making
the determination of efficacy not definitive.
1NWJ Group, LLC, Wayne, Pennsylvania.
2University of North Carolina (UNC) at Chapel Hill, Chapel Hill, North Carolina.
3Bill and Melinda Gates Foundation (BMGF), Seattle, Washington.
4Prevention Sciences Program (PSP), Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH), Bethesda, Maryland.
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Conversely, oral TDF/FTC failed to protect HIV-negative
women in the FEM-PrEP trial and VOICE.5,6 Although oral
TFV (300 mg TDF) was shown to be efficacious in the Partners
PrEP study,4 its evaluation was discontinued in the VOICE
study due to futility.6
Possible reasons for these discordant results with the same
products in different studies could include differences in
dosing regimens, trial designs, trial populations, behavior and
sexual practices, and different levels of adherence in the trial
populations. Thus, the need for more robust assessments of
efficacy potential for next-generation, high-impact, HIV pre-
vention products earlier in clinical development remains a
priority for the field.
Although proper preclinical development and clinical
safety assessment of ARV-based prevention products have
been achieved for a number of products, meaningful evalua-
tion of the efficacy potential of such products, prior to Phase 3
trials, remains elusive. The efficacy of prevention products
can be influenced by a number of factors including dose and
product exposure, target cell bioavailability, tissue perme-
ation in the compartments of HIV exposure, in vivo half-life,
protein binding, effects of biological fluids, local immune re-
sponses, and perhaps most complex of all, the behaviors af-
fecting consistent use of the product. Unfortunately, typical
Phase 2 proof-of-concept study designs based on products for
treatment indications are not feasible for prevention products,
given the number of participants required to establish the
statistical significance of a prevention outcome. Conse-
quently, the prevention field has relied on limited, alternative
means of assessing efficacy potential earlier in the drug de-
velopment pipeline, which include the use of animal models8
or ex vivo tissue explant systems.9 At best, these systems have
provided limited insight to assess safety as well as efficacy
potential as influenced by dose, dosing regimen, and in vivo
properties of the drug candidates. None of the models has yet
been conclusively validated against clinical outcomes in
human Phase 3 trials. Improving the robustness and accurate
assessments of product pharmacokinetics (PK) and pharma-
codynamics (PD) in humans and animal models may provide
a relevant, useful, and earlier means of identifying safe and
effective HIV prevention products.
Determination of in vivo ARV concentrations in various
compartments after clinical dosing has occasionally been in-
cluded in early prevention product trials, but typically it has
progressed in parallel with larger efficacy studies. Often, it
has been considered as a follow-up analysis of samples col-
lected from efficacy studies. In most instances, these samples
are plasma and occasionally include peripheral blood mono-
nuclear cells (PBMCs), whole tissue biopsies, or HIV target
cells isolated from target mucosal sites. Even vaginal/rectal
secretions are rarely collected. Also, when included as part of
early clinical evaluation, such trials typically involved sexu-
ally abstinent participants, which negated the ability to de-
termine the effects of sexual intercourse on drug levels in the
gastrointestinal and genital tract. While these limited PK
measurements may be useful in understanding outcomes
posttrial, the field needs improved pre-Phase 3 methods to
better inform efficacy trial design and more accurately predict
efficacy outcomes. The development of more robust human
and animal PK/PD assessment systems will provide a better
understanding of the relationship between drug concentra-
tions and activity, as well as the effects of dose and drug
exposure on clinical outcome.
To define the critical issues relevant to the development of
effective PK/PD models for use in HIV prevention, the
National Institute of Allergy and Infectious Diseases (NIAID),
Division of AIDS (DAIDS), Prevention Sciences Program
(PSP) at the National Institutes of Health (NIH) in collabora-
tion with the Bill and Melinda Gates Foundation (BMGF)
sponsored an Antiretroviral Pharmacology in HIV Preven-
tion Think Tank. This article outlines the major issues ad-
dressed at this meeting with particular focus on the details of
conventional derivation and use of PK/PD models and data
in drug development, the current state of such models and
their use in the HIV prevention field, and the PK/PD
knowledge and capability gaps in HIV prevention that need
to be addressed.
PK/PD in Drug Development
The determination of drug-candidate PK and PD, and the
relationships between the two (i.e., a particular concentration
of drug in vivo yields a specific level of effect/efficacy), is a
fundamental component of drug product development.
Typically, PK/PD evaluations are initially conducted in ani-
mal models. However, PK/PD relationships can be compli-
cated by species differences between animal models and
humans [e.g., differences in absorption, distribution, metab-
olism, and excretion (ADME), plasma to effect site ratios, and
protein binding, immune responses]. Consequently, clinical
studies are the definitive determination of the PK/PD rela-
tionship in humans. Once drug concentrations over a partic-
ular time course are derived for specific doses in animals,
exposure–response relationships can be analyzed in various
ways. Given the lack of a proof of concept outcome in phase 2
PrEP studies, there is increased need to appropriately study
PK/PD relationships with prevention products in order to
inform development decisions for such products.
Table 1. Recent HIV-Prevention Product Efficacy Trial Results
Study Product (dosing frequency) Population Efficacy result
CAPRISA 0041 1.0% TFV Gel (‘‘BAT-24’’) HIV-negative women 39%, p = 0.017; 95% CI: 6–60%
iPrEx3 Oral Truvada (daily) HIV-negative MSM 44%, p = 0.005; 95% CI: 15–63%
Partners PrEP4 Oral Truvada (daily) Serodiscordant couples 62%, p = 0.0003; 95% CI: 34–78%
Oral TDF (300 mg) (daily) 73%, p < 0.0001; 95% CI: 49–85%
TDF2 Study7 Oral Truvada (daily) HIV-negative women and men 63%, p = 0.013; 95% CI: 22–83%
Fem PrEP5 Oral Truvada (daily) HIV-negative women Early termination
VOICE2,6 Oral TFV (daily) 1.0% TFV gel (daily) HIV-negative women Early termination
MSM, men who have sex with men.
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This type of analysis is routinely performed for antimicro-
bials, where a dose-fractionation study design is commonly
implemented first. With this approach, a fixed total daily dose
of antimicrobial is administered as a single dose or fraction-
ated into smaller doses administered using different dosing
intervals. Based on such studies, the antibacterial drugs can be
classified according to the correlation between the effect (most
often defined as the bacterial count after 24 h of treatment)
and three main PK/PD indices: (1) the ratio of the maximal
unbound (free) drug concentration (Cmax) to the minimum
inhibitory concentration (MIC) (fCmax/MIC), (2) the ratio of
the area under the unbound drug concentration–time curve
(AUC) to the MIC [f(AUC)/MIC], or (3) the percentage of a
24-h time period that the unbound drug concentration ex-
ceeds the MIC (fT > MIC) (Table 2).10–12 Typically, the ap-
proach closest to a linear relationship of drug concentration
and effect (generally, a decrease in colony-forming units for
bacterial infection) is identified as having the most predictive
value for measuring the biological effect of the drug on the
pathogen. Although this approach is routinely used to study
antimicrobial agents, such an evaluation of anti-HIV drugs
would be more challenging given the lack of robust assays for
measuring pharmacodynamics in samples from clinical trials.
Importantly, individual drugs (or classes of drugs) with
different physicochemical properties or mechanisms of action
may display different efficacy outcomes with these alternative
means of analysis. Thus, until proven, it should not be as-
sumed that the relationships observed with one particular
anti-HIV drug will be the same as another such drug. Until
more data are available, it is recommended that each drug in
development be individually evaluated by these PK/PD as-
sessment strategies.
There are a number of important variables to consider in
the application of these PK/PD assessment strategies as a step
toward identifying optimal prevention interventions. First,
knowing the amount of free drug and the amount of total
drug in the test system is relevant to understanding the out-
come. Presumably, a drug that is bound to another molecule
in a model system is not available to exert a biological effect, at
least not as potently as a free drug. Differences in protein-
binding affinity of different ARVs have been well docu-
mented13 and would likely be relevant in the application of
such drugs for prevention. Thus, methods of measuring drug
concentrations that do not account for free versus total drug
concentrations, particularly in the compartments of effect,
may lead to biased drug requirement recommendations.
Second, it is also important to understand the effects of the
immune system on biological outcomes, particularly in the
evaluation of drugs targeting infectious agents. If measured
effects in an in vivo system are a composite of drug effects and
innate or adaptive immunity, then assessment of true drug
effect alone could be confounded. This issue can complicate
results further since immune responses are not typically uni-
form across different species, or even between individuals of
the same species. The use of immune-suppressed, animal-
model systems may also complicate effect outcomes. Thus,
understanding both protein binding and the immune re-
sponse in PK/PD model systems is relevant to interpreting
the overall findings from such studies. Several different types
of immune responses have been described.14 However, their
contribution to the measured efficacy is further complicated
by the absence of a clear immune correlate of protection
for HIV.
Other variables are also relevant to the application of PK/
PD models in drug candidate evaluation. Since a drug dis-
tributes to different body sites at different rates, single time-
point-based assessments can be misleading. Therefore, it is
important to assess exposure across the entire dosing interval
using multiple time points. Aside from potentially providing
a higher degree of accuracy, assessments over time support
the derivation of dosing regimens that are optimized for the
duration of effect. This is particularly relevant for the evalu-
ation of chronic, intermittent, or episodic use of oral or topical
products. For the purpose of this article, we define episodic as
the use of PrEP in an on-demand fashion relative to sexual
intercourse. We define chronic dosing as a dose schedule that
may include either daily use or sustained release of drugs.
Intermittent dosing is the use of a PrEP product for one or
more days followed by a variable period of nonuse. In the case
of infectious disease indications, studies over time may also be
relevant to assessing the risk of resistance since selection of
resistance can occur at subtherapeutic concentrations of in-
hibitory drugs.15
It is also important to understand the relationship between
drug plasma concentrations (the typical target in PK assess-
ments) and the concentrations in tissue or cell compartments
where prevention is mediated. Blood may serve as the means
of compartment supply; however, it is not necessarily the case
that the amount of drug in plasma at a given time point is the
same as that in a particular compartment of effect. This is
relevant for an HIV prevention indication (particularly at the
earliest time points after dosing), which will rely on specific
drug concentrations in compartments of viral exposure—as
opposed to a treatment effect, which depends more on
chronically established plasma concentrations necessary to
suppress ongoing viral replication in the periphery.16
When constructing dose-fractionation or escalation studies
in these model systems, it is important to be sure that the full
dynamic range of effect is evaluated from a drug concentra-
tion perspective. Establishing a concentration curve that
spans the range of no effect up through maximal effect is
critical to dose evaluation and selection. It is also important to
understand the elimination kinetics of a drug. The decaying
exposure over time could be relevant to medical management
of individuals using the product, the understanding of po-
tential risks associated with prescribed product use, as well as
potential risks associated with variable adherence. Drug
concentrations below the protective target could allow for
Table 2. Pharmacokinetic/Pharmacodynamic
Relationships Used to Predict Antibiotic Efficacy
AUC/MIC AUC obtained from plotting in vivo drug
concentrations over a fixed time period,
divided by the MIC of drug against a
specific pathogen
Cmax/MIC The Cmax measured in vivo over a specific
time period, divided by the MIC of a
drug against a specific pathogen
Time > MIC The duration of time that in vivo drug
concentrations are measured to be
greater than the MIC of drug against
a specific pathogen
AUC, area under the curve; MIC, minimum inhibitory concentration.
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HIV infection, and the presence of these suboptimal concen-
trations in an HIV-positive individual could lead to the in vivo
selection of resistant virus.
Another major challenge confronting PK assessments in
tissue samples for a prevention indication is the fact that tis-
sues themselves are multicompartmental, and only very
specific subcompartments are susceptible to HIV infection
(e.g., the CD4 + /CCR5 + cell populations). Tissues are com-
prised of multiple cell types (immune, nonimmune, etc.),
blood, and interstitial fluids. However, drug distribution may
not be homogeneous throughout these distinct compartments
and the cells within them. Thus, the simple homogenization of
tissue samples followed by drug concentration determination
may not be reflective of the true potential for target cell pro-
tection against HIV.
Intratarget cell drug concentrations are particularly im-
portant for prodrugs such as TFV, which require intracellular
conversion to an active form and to other agents that may be
substrates of uptake and efflux transporters. Similarly, drugs
that inhibit active HIV replication also need to establish in-
hibitory intracellular concentrations. In cases of topical dos-
ing, tissue sampling (e.g., genital or rectal tract samples after
gel dosing) is further complicated by a risk of cocollecting the
dosed drug present in the extracellular fluids associated with
these tissue samples. The presence of drug in these fluids may
result in an overestimation of drug exposure associated with
the tissue sample. However, if a consistent relationship be-
tween these fluids and tissues can be documented, and the
same sampling method is utilized across preclinical and
clinical studies, the concentration obtained may be a viable
surrogate of efficacy. Therefore, sample collection and pro-
cessing methods are extremely relevant in the use of PK/PD
model systems and must be carefully controlled and im-
plemented in order to avoid obtaining biased results.
Results from studies involving different sample collection,
processing, and analysis procedures may not be readily
compared due to the potential variability inherent in the in-
dividual methods. The pharmacology of HIV prevention is
further complicated since the target cells (such as tissue-based
activated CD4 + /CCR5 + lymphocytes) regularly circulate in
and out of the compartments of exposure. Thus, the drug
needs to be available at all times to those cells entering the
compartment to achieve protective levels in those target cells.
In the absence of validated processes for isolating cells from
tissue, which ensures that intracellular concentrations remain
unaltered during laboratory processing, it may be necessary
to consider the contribution of blood and extracellular fluid
concentrations to the results obtained in the analysis of gross
sample homogenates.
The relevance of drug concentrations in specific compart-
ments (or subcompartments) at the site of HIV exposure may
be informed by the study of antibiotics in specific compart-
ments and their antimicrobial effects. It is clear from multiple
studies that curing of a bacterial infection likely involves more
complicated phenomena than simply reaching a specific drug
concentration at the site of infection. For example, the pres-
ence of drugs in the epithelial lining fluid (ELF) of lung tissue
is relevant to the treatment of lower respiratory tract infec-
tions since ELF is often the site of extracellular infections.17
Thus, for a specific indication, the appropriate biological tar-
gets for drug measurement cannot be assumed; they must be
determined. Once the relevant compartment of effect has been
identified, it is necessary to develop methods for specifically
measuring exposure to understand the kinetics of penetration
in these target subcompartments.18 For drugs requiring in-
tracellular activation (or drugs that inhibit HIV intracellularly)
it will be necessary to determine their concentrations in spe-
cific target cells (e.g., activated versus resting CD4 + /CCR5 +
T cells), which is particularly complex from an analytical
perspective. Moreover, measuring clinical intracellular con-
centrations of drugs at the time of viral exposure is an even
more complex challenge.
Many of the types of assessments described above could be
achieved with HIV prevention products through the use of
appropriate animal models. Potential advantages of animal
models include reasonable and workable sample sizes due to
efficient (e.g., 80–100%) infection rates with a fixed number of
viral exposures, the ability to conduct diverse virus chal-
lenges, and the capacity to comprehensively collect samples.
However, animal models for a prevention indication could be
more challenging to develop and optimize than those used for
a treatment indication. To correlate findings in animal models
to humans, it is necessary to understand the complex vari-
ables that control drug distribution and metabolism at a
specific tissue site, as well as physiological and biological
differences between systems. The following section summa-
rizes the details of some of the animal models used to study
HIV infection and evaluate candidate-prevention products.
The challenges and gaps with these models are also described.
Animal Models for HIV Infection
In vivo models for efficacy: nonhuman primate (NHP)
The NHP model is one of the earliest established in vivo
animal systems used to evaluate the efficacy of oral and top-
ical prevention products. This model allows the assessment of
blood/plasma and mucosal fluid/tissue drug concentrations
in both cervicovaginal and rectal transmission.8 The NHP
system has some important limitations as an infection model.
First, it typically requires challenge with an engineered virus
[R5 or X4 tropic env simian/human immunodeficiency virus
(SHIV), or RT SHIV]. Thus, viral challenge involves a single
virus species, unlike the quasispecies that occur in human
exposure, and the virus inoculum in this model is higher than
human exposure with sex. Second, primarily due to costs, the
number of animals routinely used per study arm is low,
limiting the derivation of statistically meaningful results.
Finally, viral challenge is not usually achieved in the presence
of semen, nor does it involve coitus or coinfection with other
sexually transmitted infections. The model has been devel-
oped primarily to support challenge with free virus, and most
studies do not involve challenge with infected cells.
There are two versions of the vaginal challenge model
currently being used, a multidose and a single dose. The single-
dose virus challenge can be applied after preliminary treat-
ment of rhesus macaques with medroxyprogesterone (or
Depo-Provera), which enhances infection potential,8 and
prior treatment with the test product (e.g., ‡ 30 min before
challenge). The multidose viral challenge model involves re-
peated viral exposures at a lower multiplicity of infection over
time in pigtailed macaques (no Depo-Provera pretreatment)
after application of the test product.19 Neither of these ap-
proaches is a direct parallel to human exposure, and both are
potentially complicated by the anatomical, histological, and
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physiological differences between the macaque and the hu-
man female reproductive tracts. Despite these issues with
both NHP models, they have been used in a number of studies
to evaluate ARV-based prevention products and strategies
(Table 3). Both single-dose and multidose versions of the chal-
lenge model are also available for rectal exposure.
A number of laboratories support the use of the single-
dose model, and several studies have been reported for a
variety of microbicide-candidate products in a variety of
formulations.20–23 This model has been used to examine
polyanion-type microbicide products, such as PRO-200024
and Carraguard-based formulations.25 In the case of the
polyanion products, low-level efficacy was reported. How-
ever, neither of these products proved efficacious in human
studies. The Depo-Provera pretreatment serves to render the
animals more susceptible to infection (likely due to epithe-
lial and mucus thinning) and synchronizes the menstrual
cycle. In this model, reproductive hormones may also influ-
ence drug absorption into genital tissues.26
Evaluation of HIV prevention products with the multidose
viral challenge model in pigtail macaques has gained atten-
tion. For example, the multidose macaque model was used to
demonstrate protective effects of both 1% TFV gel and 1%
TFV/5% FTC combination gel after vaginal application and
subsequent challenge with SHIV.19 This study demonstrated
100% efficacy for both products. PK evaluations were re-
stricted to plasma concentrations. Although the study dem-
onstrated 100% efficacy, only 76% of plasma samples
contained detectable TFV and/or FTC. A subsequent study in
the same model examined the window of protection of 1%
TFV gel and its relationship to the more relevant drug con-
centrations in vaginal tissues.27 This study demonstrated a
wide window of protection (*75% efficacy) when gel was
applied 3 days before SHIV challenge and suggested that
TFV-DP concentrations in vaginal lymphocytes that are above
the in vitro IC95 may be good predictors of protection.
27 Pro-
tection in macaques with 1% TFV gel was higher than what
was observed in the CAPRISA and VOICE trials, highlighting
the contribution of other factors including adherence and in-
flammation to lack of protection.2
More recently, this low-dose model was also used to exam-
ine the efficacy of orally dosed ARV. In a study involving
various oral-dosing regimens of TDF/FTC followed by repeat
rectal exposure to virus, protective effects were determined.
In a separate set of animals, concentrations of TFV and FTC
were measured in rectal fluid, and the active intracellular
metabolite of TFV diphosphate (TFV-DP) was measured in
rectal tissue and PBMCs after a single dose.28 Because the PK
was performed in a set of animals that was different from the
set challenged, PK/PD relationships could not be established.
However, several dosing regimens involving intermittent use
of the drug were found to be as effective as daily use in pro-
tection against rectal challenge. It was concluded that this
finding was due to the long intracellular persistence of TFV-
DP seen in macaque rectal cells. Further PK/PD correlations
in the same animal, and to human study results, are still
needed for currently investigated products and beyond.
In vivo models for efficacy: humanized mouse
In 2002, a model involving severe combined immunodefi-
ciency (SCID) mice engrafted with human peripheral blood
leukocytes was developed in which cell-associated HIV was
transmitted through vaginal exposure.29 Although the in vivo
relevance of cell-associated HIV transmission in humans is
unknown, this model was used to demonstrate the protective
effects of several candidate microbicides.29,30
Recently, more elaborate humanized mouse infection
models have been developed [the RAG-hu mice;31,32 bone
marrow/liver/thymus (BLT) mice33]. In the BLT humanized
mouse model, SCID mice are implanted with human thymus
and liver tissue followed by irradiation and infusion with
human CD34 + hematopoietic progenitor cells.33 This results
in immune reconstitution of humanized lymphoid cells in
both the female reproductive tract and gastrointestinal tract,
which can then be infected with HIV. Although relatively
high doses of virus are needed to achieve infection, there is a
clear advantage to being able to use clinical HIV isolates for
vaginal and rectal challenge, rather than the engineered
strains of SHIV used in the NHP model. Advantages of the
humanized murine models include the continuous produc-
tion of human immune cells, which allows their use in long-
term experiments, that multiple human donors can be used to
produce multiple cohorts of mice, and that multiple preven-
tion (oral and topical) strategies can be evaluated.33
Costs to generate humanized mice can rival the costs of
NHPs, as they require long periods of time for their produc-
tion. However, there is a relatively unlimited supply of this
model compared to the NHP. The anatomical restrictions of
the mouse may limit the volume and dosage forms that can be
evaluated with this model. Nonetheless, assays for quantita-
tion of drug in various matrices have been developed and
applied to this model,34 and they may be used more easily for
PK/PD assessments. Thus, humanized mouse models offer a
potential means of studying prevention efficacy in ways that
parallel but also differ from the NHP model. Furthermore,
having multiple models for comparison with the human
system helps address the limitations associated with them
individually.
The relevance of both NHP and humanized mice models to
the human system is as yet unclear. Without continued de-
velopment and characterization, the biological limitations,
as well as further benefits, of the models will be difficult to
address. Improvements needed to make these models more
robust for PK/PD use include (1) characterization and
understanding of histological and biological similarities
and differences with the human system, (2) optimization and
standardization of both sample collection and processing
methods, (3) standardization of drug treatment and virus-
challenge techniques, (4) understanding if any differences
exist in the PK/PD relationship of a given compound com-
pared to humans, and (5) expanding the data set with dif-
ferent drugs.
Human PK/PD Assessments of HIV Prevention
Product Candidates
Drug concentrations in human plasma, PBMCs, genital and
colorectal tissues, and genital and colorectal fluids have been
measured for a number of HIV prevention candidates after
clinical dosing. For example, TFV and TFV-DP were mea-
sured in plasma, cervicovaginal fluid (CVF), vaginal tissue,
and cervical cells after vaginal dosing with 4 ml of 1% TFV
gel.35 High concentrations of TFV and TFV-DP could be found





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in the genital tract over 24 h after single and multiple dosing.
In a retrospective analysis, both TFV CVF concentrations
> 1,000 ng/ml and detection of TFV in blood plasma were
associated with reduced HIV infection in the CAPRISA 004
study.36,37 Recently, the MTN 001 study demonstrated that
vaginal dosing achieved much lower plasma concentrations
and higher vaginal tissue concentrations than those achieved
with oral dosing.38 Based on these results, vaginal dosing with
TFV should provide higher concentrations of active drug in
the compartment of viral exposure than oral dosing. How-
ever, results from the VOICE trial suggest issues beyond the
antiviral effect of TFV are relevant to efficacy/effectiveness.
Plasma, genital secretions, and tissue concentrations of
TFV, TFV-DP FTC, and FTC- triphosphate (TP) have been
similarly evaluated after a single oral dose of TDF/FTC.39
Interestingly, the investigators noted divergent penetration of
FTC and TFV in vaginal/cervical and colorectal tissues. TFV
exposure in the female genital tract was similar to blood
plasma, whereas TFV exposure in colorectal tissue was 100
times higher. The same pattern was seen with intracellular
TFV-DP; concentrations were 100-fold higher in colorectal
tissue than in vaginal/cervical tissue. The opposite trend was
seen for FTC and FTC-TP; exposure in the female genital tract
was approximately five times higher than exposure in colo-
rectal tissue.
Plasma and PBMC drug concentrations have been evalu-
ated in efficacy studies involving TDF/FTC. Generally, drug
exposure is lower in those who become infected with HIV
than those who remain protected.3,4 It is difficult to extrapo-
late findings from one study to another, as different popula-
tions of subjects were followed at different time intervals and
had different sampling strategies. However, it does appear
that the divergent pharmacology of TDF/FTC in mucosal
tissues may explain the different rates of efficacy in the face of
suboptimal adherence.40 For example, the iPrEX study dem-
onstrated 44% protection in men who were only sporadi-
cally taking their daily doses of TDF/FTC; only 18% of
uninfected men in a case-cohort analysis had evidence of daily
drug taking behavior, and 52% were using < 2 doses of TDF/
FTC per week.41 Yet no efficacy was noted in the FemPrEP
study5 where 20–30% of women had evidence of recent drug
taking behavior. Similar to what was noted in macaques,27
higher colorectal penetration of TFV may not necessitate
TDF/FTC’s daily use for efficacy in MSM, whereas lower
cervical/vaginal penetration may require consistent daily
adherence for efficacy.
Recently, investigators have been testing various ap-
proaches to ex vivo PD assessments in patients receiving HIV
prevention products. For example, infection was inhibited
after an ex vivo HIV challenge of rectal biopsies obtained from
men who dosed rectally with 0.25% UC-781 gel.42 A similar
effect was noted with rectal application of 1% TFV gel.43
Rectal tissue biopsies collected 30 min after single and multi-
ple rectal dosing, as well as a single oral dosing, were ana-
lyzed for drug concentrations, and evaluated in the ex vivo
HIV challenge model.43 An increased level of protection
against HIV challenge correlated with higher tissue concen-
trations of TFV-DP. In a cell culture model, a significant in-
crease over baseline endogenous anti-HIV activity was noted
in CVL from women who had previously applied TFV gel,
and this activity correlated with TFV concentration.44 More-
over, application of a single dose of TFV topically or sys-
temically to ectocervical explants was effective at preventing
HIV infection.45
Although these ex vivo clinical studies have suggested a
correlation between drug concentration and efficacy, these
methods and models are relatively new and complex and
require further development and optimization.46 As noted
earlier, methods for collection and processing of tissue sam-
ples are extremely relevant to outcomes in terms of accurate
measurement of drug exposure in tissues. Although the typ-
ical method for processing tissue samples is homogenization,
specific cell isolation may be more informative. However,
despite technical feasibility, quantifying intracellular drug
concentrations of lipophilic compounds that accurately reflect
the original in vivo concentrations at the end of a lengthy
cellular isolation process is complex. Moreover, current ana-
lytical instrumentation require large numbers ( > 100,000) of
cells. Although these cell numbers can be isolated from 20
biopsies of colorectal tissue, the number of biopsy samples
that can be collected from the female genital tract2–4 is sig-
nificantly less. Cervical cytobrush sampling also yields small
numbers of mononuclear cells.47 Consequently, tissue collec-
tion represents a technical and quantitative challenge to the
implementation of these human PD models.
The majority of the ex vivo clinical PK/PD effort to date has
involved TFV and TDF/FTC. Therefore, the performance of
these model systems with drugs that differ in terms of phys-
icochemical properties or mechanisms of action needs to be
investigated. Also, the types of PK/PD assessments that have
been applied in human systems (i.e., dose, biopsy, ex vivo
challenge) have not been extensively evaluated in any of the
animal model systems available for the study of HIV pre-
vention. Determining if an animal tissue explant system can
predict animal efficacy would assist in interpreting and ex-
trapolating human tissue data to clinical outcomes. Expanded
study of animal models, which afford more flexibility in terms
of use, may provide significant insight into the relationships
between drug exposure and biological effect. However, the
clinical relevance of animal model data will require a cali-
bration between animal models and humans. It may be that
certain correlations are drug specific. The evaluation of more
drugs of different classes is essential to understand these re-
lationships and determine the overall utility of animal models
as predictors of effective HIV prevention strategies.
Finally, the study of PK and PD in animal or human sys-
tems for HIV prevention ideally should go beyond simple
correlations of drug concentrations in different compartments
with efficacy. Efforts should be made to understand the types
of relationships described earlier for the study of antimicro-
bials (e.g., AUC/MIC, Cmax/MIC, and time > MIC) for HIV
prevention candidates. Different drugs may have different
parameter relationships, and understanding those relation-
ships may be crucial to determining the efficacy potential of
the drug. The lesson from other systems and indications is
that the simple measure of concentration and effect (or the
assumption of effect) will likely be inadequate to predict
human efficacy outcomes in vivo. Multiple and more sophis-
ticated relationships will need to be studied.
Regulatory Aspects of PK/PD
At present, there is no regulatory requirement for animal
model data to support the efficacy claims of a product.
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Regulatory agencies recognize the utility of animal models in
the study of mechanism of action and in efforts to deter-
mine dose and dosing regimen, but it is also clear that an-
imal efficacy data are not accepted as representative of
efficacy in humans. In the case of HIV prevention, the
utility of animal models from the regulatory perspective is
dependent on the degree to which the model resembles the
human system. Of fundamental importance is whether the
animal model is representative of infection in humans. As
outlined earlier, we still do not know how current animal
infection models correlate to natural HIV infection in hu-
mans. Similarly, it is important to demonstrate that the PK
profile in the relevant compartment(s) of the animal model
can mimic human exposure. It is also essential to demon-
strate that a model can be used to characterize drugs with
different mechanisms of action and routes of administra-
tion. Thus, addressing these issues with available models is
important in establishing regulatory significance. Even if
models closely parallel human systems, regulators will still
require clinical trials.
Therefore, the ultimate benefit of such models resides in
their ability to better inform and streamline clinical study
designs. Perhaps more relevant for regulatory purposes than
animal models is the accurate assessment of product adher-
ence in clinical trials. Understanding actual product use as
opposed to prescribed product use is crucial in interpreting
the outcomes of clinical trials. Inadequate adherence to
product in trials can lead to underestimation of efficacy, and a
lack of accurate adherence data can confound the under-
standing of PK and efficacy outcomes in trials.48
Summary
To select those new HIV prevention products capable of
having the highest impact on the epidemic, it will be necessary
to assess their efficacy potential prior to Phase 3 studies with
strategies that are more robust and predictive than those used
in the past. Thus, with the overarching goal of identifying the
most appropriate new products for development and en-
hancing our ability to interpret results from clinical trials, a
better understanding of PK/PD is a key requirement. The
joint DAIDS/BMGF Antiretroviral Pharmacology of HIV
Prevention Think Tank reached the consensus that one of the
most critical needs in the field of HIV prevention is the de-
lineation of the PK relationship between human and animal
models of HIV infection. The Think Tank participants also
defined a number of key studies that could potentially ad-
dress this specific need (Table 4).
A fundamental understanding of the relationship between
drug concentration and effect (or potential effect) is critically
needed. To generate these data, assessments of antiretroviral
PK/PD in animals need to be applied over wider dose ranges,
and need to be based on accurate assessment of drug expo-
sure. Discriminating between free (e.g., protein-unbound)
and total (e.g., protein-unbound + protein-bound) drug con-
centrations, as well as accurately assessing drug exposure in
subcompartments, will require the development of sophisti-
cated sample collection, processing, and analysis techniques.
A wider array of drugs and drug classes needs to be evaluated
in these systems. Both animal and human PD models need
further development, optimization, and standardization;
there needs to be a better understanding of correlations, if any,
between these model systems.
NIAID/DAIDS and BMGF are committed to addressing
the critical priorities identified at the Think Tank so that our
ability in selecting candidate products with the highest po-
tential for impact on the epidemic, as well as understanding
results from clinical trials, may be significantly enhanced.
Under the auspices of the NIAID/DAIDS Comprehensive
Resources for HIV Microbicides and Biomedical Prevention
(CRMP) contract, an HIV Pharmacology Best Practices
Working Group has been established from a group of inter-
ested Think Tank members. This group will focus their initial
effort on the key issues described above with an emphasis on
planning studies that will attempt to establish a PK/PD re-
lationship between different animal models and between
animal models and humans.
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